World's Best Scientists 2026 revealed!
Massimo Cristofanilli

Massimo Cristofanilli

D-Index & Metrics

Medicine

D-Index
120
Citations
67871
World Ranking
3691
National Ranking
2033

Massimo Cristofanilli publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Massimo Cristofanilli sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,362 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Massimo Cristofanilli D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Massimo Cristofanilli sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 120 D-Index — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Massimo Cristofanilli is affiliated with Cornell University in the United States and has an extensive body of research primarily focused on oncology and cancer research. Their work contributes significantly to the fields of medicine as well as biochemistry, genetics, and molecular biology, with a notable emphasis on oncology and cancer-related studies.

Their research spans several specialized subfields, including oncology, cancer research, pulmonary and respiratory medicine, molecular biology, and pathology and forensic medicine. This multidisciplinary approach supports an in-depth exploration of cancer mechanisms, diagnostics, and treatments.

The main topics addressed in their research encompass:

  • Cancer Genomics and Diagnostics
  • Advanced Breast Cancer Therapies
  • Cancer Cells and Metastasis
  • HER2/EGFR in Cancer Research
  • Genetic Factors in Colorectal Cancer
  • Breast Cancer Treatment Studies
  • Cancer Immunotherapy and Biomarkers

Massimo Cristofanilli has published in several prominent scientific journals. Frequent publication venues include:

  • Cancer Research
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • The Journal of Liquid Biopsy
  • Annals of Oncology

Their recent papers reflect ongoing contributions to breast cancer research and targeted therapies. Notable publications include:

  • "The Landscape of Targeted Therapies in TNBC," 2020, Cancers
  • "Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer," 2023, Journal of Clinical Oncology
  • "ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer," 2021, Nature Communications
  • "Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives," 2022, Cancer Treatment Reviews
  • "Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study," 2022, Clinical Cancer Research

The scientist collaborates frequently with other researchers. Regular co-authors include:

  • Lorenzo Gerratana
  • Carolina Reduzzi
  • Andrew A. Davis
  • William J. Gradishar
  • Ami N. Shah

Best Publications

  • Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

    Massimo Cristofanilli;G. Thomas Budd;Matthew J. Ellis;Alison Stopeck

  • Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

    Cornelia Liedtke;Chafika Mazouni;Kenneth R. Hess;Fabrice André

  • Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

    Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim

  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro

  • Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser

  • Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi

  • Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System

    Sabine Riethdorf;Herbert Fritsche;Volkmar Müller;Thomas Rau

  • Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer

    Massimo Cristofanilli;Daniel F. Hayes;G. Thomas Budd;Mathew J. Ellis

  • Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

    Daniel F. Hayes;Massimo Cristofanilli;G. Thomas Budd;Matthew J. Ellis

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Nicholas C Turner;Dennis J Slamon;Jungsil Ro;Igor Bondarenko

  • Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer

    G. Thomas Budd;Massimo Cristofanilli;Mathew J. Ellis;Allison Stopeck

  • Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer

    Francisco J. Esteva;Vicente Valero;Daniel Booser;Laura T. Guerra

  • Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification

    Andrew D. Seidman;Monica N. Fornier;Francisco J. Esteva;Lee Tan

  • Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors

    Valentina Guarneri;Kristine Broglio;Shu Wan Kau;Massimo Cristofanilli

  • Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

    Charlotte Fribbens;Ben O’Leary;Lucy Kilburn;Sarah Hrebien

  • Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer

    Rinath Jeselsohn;Roman Yelensky;Gilles Buchwalter;Gilles Buchwalter;Garrett Frampton

  • Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.

    Manfred Kaufmann;Gunter von Minckwitz;Elefhterios P. Mamounas;David Cameron

  • International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

    S. Dawood;S. D. Merajver;P. Viens;P. B. Vermeulen

  • The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

    Ben O'Leary;Ben O'Leary;Rosalind J. Cutts;Yuan Liu;Sarah Hrebien

  • Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

    Marjorie C. Green;Aman U. Buzdar;Terry Smith;Nuhad K. Ibrahim

Frequent Co-Authors

Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
William J. Gradishar
William J. Gradishar Northwestern University
James M. Reuben
James M. Reuben The University of Texas MD Anderson Cancer Center
Naoto T. Ueno
Naoto T. Ueno University of Hawaiʻi Cancer Center
Leonidas C. Platanias
Leonidas C. Platanias Northwestern University
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Nicholas C. Turner
Nicholas C. Turner Royal Marsden NHS Foundation Trust
Thomas A. Buchholz
Thomas A. Buchholz The University of Texas MD Anderson Cancer Center
Savitri Krishnamurthy
Savitri Krishnamurthy The University of Texas MD Anderson Cancer Center
Anthony Lucci
Anthony Lucci The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in medicine but want flexible and alternative routes, there are a growing number of online degrees and career pathways in health sciences. Many programs now cater to working professionals, career changers, and those seeking advanced roles without pausing their careers.

For registered nurses aiming for more autonomy, rn to np programs offer a seamless transition from RN to nurse practitioner roles entirely online. Nurses who already have an RN credential may also consider online rn to bsn programs no clinicals, which allow them to earn a bachelor's degree without on-site clinical requirements.

Beyond nursing, there are reputable options in broader health management and nutrition. Aspiring healthcare leaders can pursue a cahme-accredited online Master of Healthcare Administration for advanced management positions. Those interested in dietetics and wellness can earn a nutrition degree online to work in public health or nutrition counseling.

These flexible learning options help make professional advancement in healthcare more accessible than ever.

Best Scientists Citing Massimo Cristofanilli

Trending Scientists